Iskalni niz:
išči po
išči po
išči po
išči po
Vrsta gradiva:
Jezik:
Št. zadetkov: 5
Lipoprotein(a)-the crossroads of atherosclerosis, atherothrombosis and inflammation
Sabina Ugovšek, Miran Šebeštjen
Pregledni znanstveni članek
Oznake: lipoprotein(a);atherothrombosis;inflammation;coagulation;fibrinolysis;
Increased lipoprotein(a) (Lp(a)) levels are an independent predictor of coronary artery disease (CAD), degenerative aortic stenosis (DAS), and heart failure independent of CAD and DAS. Lp(a) levels are genetically determinated in an autosomal dominant mode, with great intra- and inter-ethnic diversi ...
Leto: 2022 Vir: Fakulteta za farmacijo (UL FFA)
Influence of LDL cholesterol and Lp(a) on monocytes and macrophages in atherosclerosis
Sabina Ugovšek, Jernej Jeras, Miran Šebeštjen, Janja Zupan
Pregledni znanstveni članek
Oznake: atherosclerosis;monocytes;macrophages;lipoprotein(a);LDL cholesterol;
Atherosclerosis is an active interaction between lipoproteins and inflammatory cells. Monocytes and macrophages are the most important immune cells involved in the process of atherosclerosis. They interact with atherogenic lipoproteins, in particular low density lipoprotein (LDL) cholesterol and lip ...
Leto: 2025 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Effect of PCSK9 inhibitors on regulators of lipoprotein homeostasis, inflammation and coagulation
Patricija Lunar, Hana Meglič, Mateja Vehar, Sabina Ugovšek, Andreja Rehberger Likozar, Miran Šebeštjen, Janja Zupan
Izvirni znanstveni članek
Oznake: PCSK9 inhibitors;lipid regulators;inflammation;coagulation;coronary artery disease;
Background: PCSK9 inhibitors (PCSK9i) represent a newer form of atherosclerosis treatment. Inflammation and haemostasis are key processes in the development of atherosclerosis. In this study, we investigated the influence of therapy with PCSK9i in patients with coronary artery disease (CAD) on regul ...
Leto: 2025 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins
Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan, Slobodan Antonić, Miran Šebeštjen
Izvirni znanstveni članek
Oznake: polimorfizmi PCSK9;lipoprotein(a);endotelijska disfunkcija;skupne ravni PCSK9;PCSK9 polymorphisms;endothelial dysfunction;total PCSK9 levels;
The proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates lipid metabolism, inflammation and haemostasis. Pathogenic gain-of-function variants in the PCSK9 gene are causative of autosomal-dominant form of familial hypercholesterolemia, while several PCSK9 alleles have been associated with ...
Leto: 2025 Vir: Fakulteta za farmacijo (UL FFA)
Vericiguat Therapy Is Associated with Reverse Myocardial Remodeling in Chronic Heart Failure with Reduced Ejection Fraction
Tine Bajec, Neža Žorž, Sabina Ugovšek, Gregor Zemljič, Andraž Cerar, Sabina Frljak, Renata Okrajšek, Petra Sušanj, Miran Šebeštjen, Bojan Vrtovec, Gregor Poglajen, Gregor Poglajen
Izvirni znanstveni članek
Oznake: heart failure;myocardial reverse remodeling;soluble guanylate cyclase stimulator;
Background and aims: Vericiguat lowers cardiovascular death or heart-failure hospitalization in recently worsened heart failure with reduced ejection fraction (HFrEF), but its effects on cardiac remodeling are less well characterized. Our aim was to evaluate whether the addition of vericiguat to gui ...
Leto: 2026 Vir: Repozitorij Univerze v Ljubljani (RUL)
Št. zadetkov: 5
Ključne besede:
Leto izdaje:
Avtorji:
Repozitorij:
Tipologija:
Jezik: